BiotechTube

LY2780301

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastases, Neoplasm

Conditions

Metastases, Neoplasm

Trial Timeline

Mar 1, 2010 → Jul 1, 2012

NCT ID
NCT01115751

About LY2780301

LY2780301 is a phase 1 stage product being developed by Eli Lilly for Metastases, Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT01115751. Target conditions include Metastases, Neoplasm.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01115751Phase 1Completed

Competing Products

20 competing products in Metastases, Neoplasm

See all competitors
ProductCompanyStageHype Score
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
41
Patritumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
77
Leuprorelin AcetateAstellas PharmaPhase 3
77
Pembrolizumab + LenvatinibEisaiPhase 2
52
ALIMTA + folic acid + multi-vitaminsEli LillyPhase 1
33
MerestinibEli LillyPhase 1
33
LY2584702 + Erlotinib + EverolimusEli LillyPhase 1
33
Veliparib + PlaceboAbbViePhase 2
52
temozolomideMerckPhase 2
52
VorinostatMerckPhase 1
33
PembrolizumabMerckPhase 2
52
EMD 525797MerckPhase 1
33
TemozolomideMerckPhase 2
52
cabazitaxel + lapatinibNovartisPhase 2
52
BKM120 + capecitabine + TrastuzumabNovartisPhase 2
52
Zoledronic acidNovartisPhase 3
77
zoledronic acidNovartisPhase 1
33
capecitabine + lapatinib + trastuzumabNovartisPhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85